Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Atsena Therapeutics

Private
#Ophthalmology#Gene Therapy#Inherited Retinal Disease

Clinical-stage gene therapy company developing treatments to reverse or prevent blindness, including programs for X-linked retinoschisis, GUCY2D-associated blindness and MYO7A-associated Usher syndrome.

Company Info

Sector:Gene Therapy / Ophthalmology
Headquarters:Durham, North Carolina, United States
Founded:2019
Website:atsenatx.com/

Clinical Development Pipeline

ATSN-101

Target: RS1
X-linked retinoschisis
Preclinical
Phase 1
Phase 2
Phase 3
Approved

ATSN-201

Target: GUCY2D
GUCY2D-associated Leber congenital amaurosis
Preclinical
Phase 1
Phase 2
Phase 3
Approved

ATSN-301

Target: MYO7A
MYO7A-associated Usher syndrome type 1B
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Patrick Ritschel

Chief Executive Officer

Kenji Fujita

Chief Medical Officer

Shannon Boye

Founder and Chief Scientific Officer

Careers & Job Openings

See all open roles

All departments
See posting
Apply Now →